Loading...
Mortality rates associated with heart failure (HF) remain high, despite multiple evidence-based therapies to improve outcomes. Existing models for predicting survival in HF vary in the clinical parameters they use and the care environments where they’ve been validated, and they have limitations in predictive accuracy. These researchers took a comprehensive, multivariable approach to developing and validating a HF risk model in outpatients, called the Seattle Heart Failure Model (SHFM).
Demographic, clinical, laboratory, and medication- and device-related predictors of survival were derived from the 1125-subject database of the Prospective Randomized Amlodipine Survival Evaluation trial (N Engl J Med 1996; 335:1107). Prospective validation wa…